Trial reportClinical pharmacology and therapeutics2011
Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films.
Trial report in Clinical pharmacology and therapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03740243 (Comparison of Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology), which is not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Management of opioid use disorder and associated conditions among hospitalized adults: A Consensus Statement from the Society of Hospital Medicine.Journal of hospital medicine · 2022Pooled it
- Pharmacological therapies for management of opium withdrawal.The Cochrane database of systematic reviews · 2018Pooled it
- Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.Addiction (Abingdon, England) · 2014Trial
- Street Pharmacology: The Mechanistic Basis of Clinical Pharmacology Underlying the Microdosing Method of Buprenorphine-Naloxone With a Focus on the Unhoused Population.Journal of clinical pharmacology · 2026Review
- Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine.Neuropharmacology · 2019Review
- Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2018Review
- Buprenorphine treatment formulations: Preferences among persons in opioid withdrawal management.Journal of substance abuse treatment · 2018Article
- Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men.Addiction & health · 2018Article
- New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.Substance abuse and rehabilitation · 2015Review
- Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain.Journal of pain research · 2015Review
- Self-management of buprenorphine/naloxone among online discussion board users.Substance use & misuse · 2014Article
- A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes.Substance abuse : research and treatment · 2013Article
- Comment on "a comparison of buprenorphine + naloxone to buprenorphine and methadone in the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes".Substance abuse : research and treatment · 2013Article
- Assessment of a formulation designed to be crush-resistant in prescription opioid abusers.Drug and alcohol dependence · 2012Article
- The effect of environmental factors on morphine withdrawal in C57BL/6J mice: running wheel access and group housing.Psychopharmacology · 2012Article
- The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review.Drug and alcohol dependence · 2011Review
- The worldwide opioid epidemic: implications for treatment and research in pregnancy and the newborn.Paediatric drugs · 2011Article
- Thermal sensitivity as a measure of spontaneous morphine withdrawal in mice.Journal of pharmacological and toxicological methodsArticle
- Clinician beliefs and attitudes about buprenorphine/naloxone diversion.The American journal on addictionsArticle
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
A sublingual soluble-film formulation of buprenorphine/naloxone (B/N) has been approved by the US Food and Drug Administration for the treatment of opioid dependency. This preparation provides unit-dose, child-resistant packaging amenable to tracking and accountability, offers more rapid dissolution, and has a potentially preferred taste vs. tablets. This study compared the ability of buprenorphine (B) and B/N films to suppress spontaneous withdrawal in opioid-dependent volunteers. Participants were maintained on morphine and underwent challenge sessions to confirm sensitivity to naloxone-induced opioid withdrawal. Subjects were randomized to receive either B (16 mg, n = 18) or B/N (16/4 mg, n = 16) soluble films for 5 days. The primary outcome measure was the Clinical Opiate Withdrawal Scale (COWS) score. Thirty-four subjects completed induction onto soluble films. There was a significant decrease in COWS scores but no significant differences between the groups. The results support the use of B and B/N soluble films as safe and effective delivery methods for opioid induction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.